What if tumour tissue has its own pathologically stable state?

Abstract and research question

The central OSD question is whether some cancer-associated processes can be operationalised across tissues as a measurable axis between sustained tissue burden and loss of organisational functions. The main manuscript tests this question using public molecular and clinical data; a separate laboratory protocol sets out how the hypothesis could be tested biologically.

Cancer is more than one signal

Tumour processes involve genetic alterations, proliferation, immune evasion, metabolic adaptation and remodelling of surrounding tissue. These levels are not mutually exclusive alternatives. OSD (Organism Stability Disruption) seeks a shared, measurable description at the tissue-state level: whether persistent inflammatory alarm, hypoxia, fibrosis or disrupted tissue renewal form a recognisable axis of pathology.

From concept to a measurable hypothesis

The framework separates instability-load modules from tissue-order-maintenance modules. The former include inflammatory and interferon responses, wound repair and extracellular matrix, coagulation, hypoxia and cellular stress. The latter include polarity, adhesion, circadian organisation, mitochondrial homeostasis and differentiation. Here, OSD is a research proxy for tissue state, not a direct measurement of the entire organism.

Why proliferation must be accounted for

A rapidly growing tumour may show elevated activity in many genes simply because its cells divide intensively. To avoid conflating OSD with a conventional proliferation signal, a residual version of the indicator statistically accounts for the proliferation contribution. The detailed manuscript reports analyses of public expression, clinical and other biological data sources.

The results framework and its limitations

The author's analysis reports higher raw scores in tumours at 11 of 13 tissue sites and higher residual scores at 9 of 13 after statistically accounting for proliferation. An analysis of 8,893 primary tumours with survival data reported an association between higher residual OSD and worse overall survival. These are associations in retrospectively analysed data, not evidence of therapeutic effects.

Laboratory testing should separate proliferation changes from effects on the proposed stress and repair modules, and include control conditions, reproducibility and biologically independent indicators. Until such results are available, OSD cannot be described as a validated therapeutic mechanism.

What the results show so far

According to the author's TCGA/GTEx evaluation, raw OSD was higher in tumour samples at 11 of 13 tissue sites; residual OSD remained higher at 9 of 13. In a cohort of 8,893 primary tumours with survival data, higher residual OSD was associated with worse overall survival (stratified Cox model: HR 1.110 per standard deviation; p = 1.50 × 10⁻⁷). These are retrospective associations, not an established cause or a clinically validated test.

What would genuinely test the theory

The decisive next step is not another striking correlation, but independent replication and a controlled perturbation–rechallenge experiment: target a selected module, track whether the proposed tissue state shifts, and test whether the change is reproducible after another challenge. Without that testing, a tumour “reset” or therapeutic mechanism cannot be claimed.

Read also

Detailed OSD 2026 results →

The opening graphic is a conceptual thematic illustration, not an experimental record.